Table 6. Distribution of activator and inhibitor KIR genes and related combination with HLA ligands among HCV-negative individuals and patients with HCV infection.
| KIR / HLA—ligand pairs | HCV—neg No. (%) | HCV patients | |||
|---|---|---|---|---|---|
| Chronic HCV No. (%) | Hepatocellular carcinoma No. (%) | Lymphoproliferative disorder No. (%) | |||
| Total patients | 501 (100.0) | 125 (100.0) | 118 (100.0) | 153 (100.0) | |
| Inhibitor KIR | |||||
| 2DL3/2DL2/2DL1/3DL1 | All expressed | 215 (42.9) | 41 (32.8) | 47 (39.8) | 73 (47.7) |
| At least one no expressed | 286 (57.1) | 84 (67.2) | 71 (60.2) | 80 (52.3) | |
| P-value a | Ref. | ns | 0.01 | ||
| HLA ligands: | |||||
| HLA-C2 | Present | 149 (69.3) | 29 (70.7) | 37 (78.7) | 49 (67.1) |
| Not present | 66 (30.7) | 12 (29.3) | 10 (21.3) | 24 (32.9) | |
| P-value a | Ref. | ns | ns | ||
| HLA-C1 | Present | 171 (79.5) | 30 (73.2) | 34 (72.3) | 58 (79.5) |
| Not present | 44 (20.5) | 11 (26.8) | 13 (27.7) | 15 (20.5) | |
| P-value a | Ref. | ns | ns | ||
| HLA-Bw4 | Present | 142 (66.1) | 32 (78.1) | 30 (63.8) | 47 (64.4) |
| Not present | 73 (33.9) | 9 (21.9) | 17 (36.8) | 26 (35.6) | |
| P-value a | Ref. | ns | ns | ||
| Activator KIR | |||||
| 2DS2/2DS1/3DS1 | All expressed | 130 (25.9) | 32 (25.6) | 28 (23.7) | 29 (19.0) |
| At least one no expressed | 371 (74.0) | 93 (74.4) | 90 (76.3) | 124 (81.0) | |
| P-value a | Ref. | ns | ns | ||
| HLA ligands: | |||||
| HLA-C2 | Present | 93 (71.5) | 20 (62.5) | 18 (64.3) | 19 (65.5) |
| Not present | 37 (28.5) | 12 (37.5) | 10 (35.7) | 10 (34.5) | |
| P-value a | Ref. | ns | ns | ||
| HLA-C1 | Present | 100 (76.9) | 27 (84.4) | 24 (85.7) | 23 (79.3) |
| Not present | 30 (23.1) | 5 (15.6) | 4 (14.3) | 6 (20.7) | |
| P-value a | Ref. | ns | ns | ||
| HLA-Bw4 | Present | 93 (71.5) | 25 (78.1) | 14 (50.0) | 17 (58.6) |
| Not present | 37 (28.5) | 7 (21.9) | 14 (50.0) | 12 (41.4) | |
| P-value a | Ref. | 0.03 | ns | ||
a Fisher’s exact test with chronic HCV infection as reference.